Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
MET inhibitors for non-small cell lung cancer

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.12
Views: 3332
Rating:

Prof Georgio Scagliotti – University of Torino, Italy

Prof Georgio Scagliotti talks to ecancer at the 2012 ESMO meeting in Vienna about a phase III study that looked at treating small cell lung cancer patients with MET inhibitors in the second and third line setting.

 

In the trial, patients received erlotinib and tivantinib against MET vs erlotinib alone. The phase III study included molecular analysis, of cMET and collected tissue samples from all patients for further study.

 

Prof Scagliotti also discsses the links between KRAS and MET.

To view our education modules for nurses to help prevent tobacco use, please click on this link: Nursing education modules

Filming supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation